A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis

Inflammopharmacology. 2023 Apr;31(2):745-754. doi: 10.1007/s10787-023-01148-6. Epub 2023 Mar 3.

Abstract

Pyroptosis is an inflammasome-induced lytic form of programmed cell death, and its main effect involves the release of inflammatory mediators when a cell dies, resulting in an inflammatory response in the body. The key to pyroptosis is the cleavage of GSDMD or other gasdermin families. Some drugs can cause cleavage GSDMD or other gasdermin members cause pyroptosis and suppress cancer growth and development. This review explores several drugs that may induce pyroptosis, thereby contributing to tumor treatment. Pyroptosis-inducing drugs, such as arsenic, platinum, and doxorubicin, were used originally in cancer treatment. Other pyroptosis-inducing drugs, such as metformin, dihydroartemisinin, and famotidine, were used to control blood glucose, treat malaria, and regulate blood lipid levels and are effective tumor treatments. By summarizing drug mechanisms, we provide a valuable basis for treating cancers by inducing pyroptosis. In future, the use of these drugs may contribute to new clinical treatments.

Keywords: Anti-cancer; Gasdermin family; Pharmacology; Pyroptosis.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Gasdermins
  • Humans
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Neoplasm Proteins / metabolism
  • Pyroptosis*

Substances

  • Intracellular Signaling Peptides and Proteins
  • Gasdermins
  • Neoplasm Proteins
  • Antineoplastic Agents